Back to companies

Biohaven Pharmaceutical Holding Company Ltd: Overview

Want to continue viewing company data?

Sign up for exclusive competitve intelligence.

Create account

Biohaven Pharmaceutical Holding Company Ltd (Biohaven) is a clinical-stage biopharmaceutical company. The company develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant for the acute treatment of migraine, and zavegepant for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole and BHV-4157 for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Headquarters United States of America

Address 215 Church St, New Haven, Connecticut, 06510-1803


No of Employees 825

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BHVN (NYSE)
Revenue (2020) $63.6M 0.0% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX -45.0% (2020 vs 2019)

Market Cap* $8.9B

Net Profit Margin (2020) XXX 0.0% (2020 vs 2019)

* As of and is in US$

Products and Services

Products
Pipeline
Rimegepant (BHV-3000):
Migraine
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In January, the company entered into an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab.
2021 Acquisitions/Mergers/Takeovers In January, the company announced the acquisition of remaining 58% stake in Kleo Pharmaceuticals, Inc.
2020 Contracts/Agreements In November, the company entered into a partnership with the National Ataxia Foundation to help the nonprofit organization launch the NAF Drug Development Collaborative.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Biohaven Pharmaceutical Holding Company Ltd La Jolla Pharmaceutical Company Athersys Inc Arena Pharmaceuticals Inc Astellas Institute for Regenerative Medicine
Headquarters United States of America United States of America United States of America United States of America United States of America
City New Haven Waltham Cleveland San Diego Westborough
State/Province Connecticut Massachusetts Ohio California Massachusetts
No. of Employees 825 59 97 363 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Image for loader
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Declan Doogan Chairman Executive Board 2013 69
Vlad Coric, MD Director; Chief Executive Officer Executive Board 2015 50
James Engelhart Treasurer; Chief Financial Officer Senior Management 2016 57
Cliff Bechtold General Manager - Biohaven Ireland; Chief Compliance Officer; President - Biohaven Ireland Senior Management - -
Elyse Stock Chief Medical Officer Senior Management 2019 63
Non Dignissim Eros Proin vel Convallis 2021 XX
Non Dignissim Eros Proin vel Convallis 2021 XX
Non Dignissim Eros Proin vel Convallis 2021 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe